Edwards Lifesciences annual revenue
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Edwards Lifesciences Revenue Growth & History (EW)
Edwards Lifesciences reported $6.07B in revenue for fiscal 2025, an increase of 11.55% from the previous fiscal year.
View full Edwards Lifesciences company overviewEdwards Lifesciences annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.07B | $628.1M | +11.55% |
| 2024 | 2024-12-31 | $5.44B | $429.5M | +8.57% |
| 2023 | 2023-12-31 | $5.01B | $546.0M | +12.23% |
| 2022 | 2022-12-31 | $4.46B | −$768.5M | −14.69% |
| 2021 | 2021-12-31 | $5.23B | $846.2M | +19.29% |
| 2020 | 2020-12-31 | $4.39B | $38.3M | +0.88% |
| 2019 | 2019-12-31 | $4.35B | $625.2M | +16.79% |
| 2018 | 2018-12-31 | $3.72B | $287.5M | +8.37% |
| 2017 | 2017-12-31 | $3.44B | $471.6M | +15.91% |
| 2016 | 2016-12-31 | $2.96B | $470.0M | +18.85% |
| 2015 | 2015-12-31 | $2.49B | $170.8M | +7.35% |
| 2014 | 2014-12-31 | $2.32B | $277.4M | +13.56% |
| 2013 | 2013-12-31 | $2.05B | $145.9M | +7.68% |
| 2012 | 2012-12-31 | $1.90B | $221.0M | +13.17% |
| 2011 | 2011-12-31 | $1.68B | $231.6M | +16.01% |
| 2010 | 2010-12-31 | $1.45B | $125.6M | +9.51% |
| 2009 | 2009-12-31 | $1.32B | $83.7M | +6.76% |
| 2008 | 2008-12-31 | $1.24B | — | — |
Edwards Lifesciences quarterly revenue
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.74B | $208.8M | +13.63% |
| Q1 2026 | 2026-03-31 | $1.65B | $235.9M | +16.70% |
| Q4 2025 | 2025-12-31 | $1.57B | $183.8M | +13.26% |
| Q3 2025 | 2025-09-30 | $1.55B | $198.7M | +14.67% |
| Q2 2025 | 2025-06-30 | $1.53B | $162.8M | +11.89% |
| Q1 2025 | 2025-03-31 | $1.41B | $82.8M | +6.23% |
| Q4 2024 | 2024-12-31 | $1.39B | $119.4M | +9.43% |
| Q3 2024 | 2024-09-30 | $1.35B | $111.0M | +8.93% |
| Q2 2024 | 2024-06-30 | $1.37B | $90.5M | +7.08% |
| Q1 2024 | 2024-03-31 | $1.33B | $108.6M | +8.89% |
| Q4 2023 | 2023-12-31 | $1.27B | $836.5M | +194.58% |
| Q3 2023 | 2023-09-30 | $1.24B | −$75.6M | −5.73% |
| Q2 2023 | 2023-06-30 | $1.28B | −$95.0M | −6.91% |
| Q1 2023 | 2023-03-31 | $1.22B | −$119.9M | −8.94% |
| Q4 2022 | 2022-12-31 | $429.9M | −$899.8M | −67.67% |
| Q3 2022 | 2022-09-30 | $1.32B | $8.8M | +0.67% |
| Q2 2022 | 2022-06-30 | $1.37B | −$2.1M | −0.15% |
| Q1 2022 | 2022-03-31 | $1.34B | $124.6M | +10.24% |
| Q4 2021 | 2021-12-31 | $1.33B | $138.0M | +11.58% |
| Q3 2021 | 2021-09-30 | $1.31B | $169.3M | +14.84% |
| Q2 2021 | 2021-06-30 | $1.38B | $451.0M | +48.76% |
| Q1 2021 | 2021-03-31 | $1.22B | $87.9M | +7.79% |
| Q4 2020 | 2020-12-31 | $1.19B | $17.6M | +1.50% |
| Q3 2020 | 2020-09-30 | $1.14B | $46.9M | +4.29% |
| Q2 2020 | 2020-06-30 | $925.0M | −$161.9M | −14.90% |
| Q1 2020 | 2020-03-31 | $1.13B | $135.7M | +13.67% |
| Q4 2019 | 2019-12-31 | $1.17B | $196.4M | +20.09% |
| Q3 2019 | 2019-09-30 | $1.09B | $187.4M | +20.67% |
| Q2 2019 | 2019-06-30 | $1.09B | $143.2M | +15.17% |
| Q1 2019 | 2019-03-31 | $993.0M | $98.2M | +10.97% |
| Q4 2018 | 2018-12-31 | $977.7M | $89.2M | +10.04% |
| Q3 2018 | 2018-09-30 | $906.6M | $85.1M | +10.36% |
| Q2 2018 | 2018-06-30 | $943.7M | $101.9M | +12.11% |
| Q1 2018 | 2018-03-31 | $894.8M | $11.3M | +1.28% |
| Q4 2017 | 2017-12-31 | $888.5M | $120.8M | +15.74% |
| Q3 2017 | 2017-09-30 | $821.5M | $82.1M | +11.10% |
| Q2 2017 | 2017-06-30 | $841.8M | $82.5M | +10.87% |
| Q1 2017 | 2017-03-31 | $883.5M | $186.2M | +26.70% |
| Q4 2016 | 2016-12-31 | $767.7M | $96.6M | +14.39% |
| Q3 2016 | 2016-09-30 | $739.4M | $123.9M | +20.13% |
| Q2 2016 | 2016-06-30 | $759.3M | $142.5M | +23.10% |
| Q1 2016 | 2016-03-31 | $697.3M | $107.0M | +18.13% |
| Q4 2015 | 2015-12-31 | $671.1M | $53.1M | +8.59% |
| Q3 2015 | 2015-09-30 | $615.5M | $8.1M | +1.33% |
| Q2 2015 | 2015-06-30 | $616.8M | $41.7M | +7.25% |
| Q1 2015 | 2015-03-31 | $590.3M | $67.9M | +13.00% |
| Q4 2014 | 2014-12-31 | $618.0M | $82.0M | +15.30% |
| Q3 2014 | 2014-09-30 | $607.4M | $111.8M | +22.56% |
| Q2 2014 | 2014-06-30 | $575.1M | $57.9M | +11.19% |
| Q1 2014 | 2014-03-31 | $522.4M | $25.7M | +5.17% |
| Q4 2013 | 2013-12-31 | $536.0M | $25.5M | +5.00% |
| Q3 2013 | 2013-09-30 | $495.6M | $47.7M | +10.65% |
| Q2 2013 | 2013-06-30 | $517.2M | $35.2M | +7.30% |
| Q1 2013 | 2013-03-31 | $496.7M | $37.5M | +8.17% |
| Q4 2012 | 2012-12-31 | $510.5M | $80.3M | +18.67% |
| Q3 2012 | 2012-09-30 | $447.9M | $35.2M | +8.53% |
| Q2 2012 | 2012-06-30 | $482.0M | $50.8M | +11.78% |
| Q1 2012 | 2012-03-31 | $459.2M | $54.7M | +13.52% |
| Q4 2011 | 2011-12-31 | $430.2M | $37.8M | +9.63% |
| Q3 2011 | 2011-09-30 | $412.7M | $63.8M | +18.29% |
| Q2 2011 | 2011-06-30 | $431.2M | $66.0M | +18.07% |
| Q1 2011 | 2011-03-31 | $404.5M | $64.0M | +18.80% |
| Q4 2010 | 2010-12-31 | $392.4M | $45.7M | +13.18% |
| Q3 2010 | 2010-09-30 | $348.9M | $23.2M | +7.12% |
| Q2 2010 | 2010-06-30 | $365.2M | $29.7M | +8.85% |
| Q1 2010 | 2010-03-31 | $340.5M | $27.0M | +8.61% |
| Q4 2009 | 2009-12-31 | $346.7M | — | — |
| Q3 2009 | 2009-09-30 | $325.7M | — | — |
| Q2 2009 | 2009-06-30 | $335.5M | — | — |
| Q1 2009 | 2009-03-31 | $313.5M | — | — |
Edwards Lifesciences revenue growth trends
Over the last five reported fiscal years, revenue grew from $4.39B to $6.07B, a compound annual growth rate of 6.70%. Edwards Lifesciences's latest reported quarter, Q2 2026, generated $1.74B in revenue, an increase of 13.63% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Edwards Lifesciences source filings ↗